Learn what MRTX1133 is, how it selectively targets the KRAS G12D mutation, and why this first-in-class, non-covalent inhibitor is reshaping the landscape of precision oncology for pancreatic, colorectal, and lung cancers.
- admin@condrug.com
- Mon - Sat: 8.00 am - 7.00 pm
We develop solutions for your clinical data needs